Investment Thesis
Sutro Biopharma faces critical financial distress with negative stockholders' equity of -$66.9M and operating cash burn of -$43M annually, creating <2 year runway absent additional capital raises. While revenue growth of 65.2% YoY demonstrates commercial progress, the company is operating at massive losses (-265% net margin) with no clear near-term profitability trajectory, indicating unsustainable fundamentals.
Strengths
- Revenue growth of 65.2% YoY demonstrates commercial traction and market acceptance
- Adequate short-term liquidity with $73.7M cash and 3.12x current ratio
- Minimal debt burden with only $4.1M long-term debt reduces refinancing risk
Risks
- Negative stockholders' equity of -$66.9M indicates technical insolvency on book value basis
- Operating cash burn of -$43M annually against only $73.7M cash creates <2 year survival window
- Massive operating losses (-204% margin) with no demonstrated path to profitability despite revenue growth
- Company dependent on capital raises or dramatic operational turnaround for viability
Key Metrics to Watch
- Operating cash flow trajectory and progress toward cash flow breakeven
- Revenue growth sustainability and gross margin expansion as product scales
- Cash balance depletion rate and timing/need for additional equity financing
Financial Metrics
Revenue
14.5M
Net Income
-38.5M
EPS (Diluted)
$-2.94
Free Cash Flow
-43.0M
Total Assets
242.0M
Cash
73.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-204.2%
Net Margin
-265.0%
ROE
N/A
ROA
-15.9%
FCF Margin
-296.2%
Balance Sheet & Liquidity
Current Ratio
3.12x
Quick Ratio
3.12x
Debt/Equity
N/A
Debt/Assets
127.6%
Interest Coverage
-22.81x
Long-term Debt
4.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:23:17.085601 |
Data as of: 2026-03-31 |
Powered by Claude AI